{
  "id": "501cdc5ac9bd75c8",
  "title": "Johnson & Johnson TECVAYLI Shows 71 % Risk Reduction In Phase 3 MajesTEC - 9 Multiple Myeloma Study",
  "description": "20260115T041500Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-01/67438528-johnson-johnson-s-tecvayli-shows-71-risk-reduction-in-phase-3-majestec-9-multiple-myeloma-study-020.htm",
  "published_at": "20260115T041500Z",
  "fetched_at": "2026-01-16T00:24:08.160649+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-01/67438528-johnson-johnson-s-tecvayli-shows-71-risk-reduction-in-phase-3-majestec-9-multiple-myeloma-study-020.htm",
    "url_mobile": "",
    "title": "Johnson & Johnson TECVAYLI Shows 71 % Risk Reduction In Phase 3 MajesTEC - 9 Multiple Myeloma Study",
    "seendate": "20260115T041500Z",
    "socialimage": "https://www.finanznachrichten.de/chart-johnson-johnson-aktie-intraday-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}